Danaher Corporation (NYSE:DHR) issued an update on its FY17 earnings guidance on Thursday morning. The company provided earnings per share guidance of $3.96-4.00 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.96.
Danaher Corporation (NYSE DHR) traded up 5.07% during midday trading on Thursday, hitting $90.41. 1,836,813 shares of the stock were exchanged. The company has a market capitalization of $62.81 billion, a P/E ratio of 28.86 and a beta of 1.03. The company’s 50 day moving average is $86.15 and its 200 day moving average is $84.21. Danaher Corporation has a 1-year low of $76.27 and a 1-year high of $91.40.
Danaher Corporation (NYSE:DHR) last issued its quarterly earnings data on Thursday, October 19th. The conglomerate reported $1.00 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.95 by $0.05. Danaher Corporation had a return on equity of 11.15% and a net margin of 12.63%. The company had revenue of $4.53 billion during the quarter, compared to analyst estimates of $4.47 billion. During the same quarter in the previous year, the firm earned $0.87 earnings per share. Danaher Corporation’s revenue was up 9.6% on a year-over-year basis. Analysts predict that Danaher Corporation will post $3.96 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 27th. Stockholders of record on Friday, September 29th will be issued a dividend of $0.14 per share. This represents a $0.56 annualized dividend and a dividend yield of 0.65%. The ex-dividend date of this dividend is Thursday, September 28th. Danaher Corporation’s payout ratio is 17.83%.
Several brokerages have issued reports on DHR. Morgan Stanley reaffirmed an overweight rating and issued a $95.00 target price (up previously from $86.00) on shares of Danaher Corporation in a research note on Friday, October 6th. Zacks Investment Research raised Danaher Corporation from a hold rating to a buy rating and set a $97.00 target price for the company in a research note on Thursday, October 5th. J P Morgan Chase & Co reaffirmed an overweight rating and issued a $95.00 target price on shares of Danaher Corporation in a research note on Friday, September 8th. Cowen and Company reaffirmed a buy rating and issued a $90.00 target price on shares of Danaher Corporation in a research note on Wednesday, October 4th. Finally, Goldman Sachs Group, Inc. (The) reaffirmed a neutral rating and issued a $83.00 target price on shares of Danaher Corporation in a research note on Tuesday, September 26th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. Danaher Corporation currently has an average rating of Buy and a consensus price target of $92.62.
In other Danaher Corporation news, insider William King sold 7,458 shares of the business’s stock in a transaction that occurred on Friday, July 21st. The stock was sold at an average price of $82.97, for a total value of $618,790.26. Following the completion of the sale, the insider now owns 18,245 shares in the company, valued at $1,513,787.65. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Linda P. Hefner sold 10,578 shares of the business’s stock in a transaction that occurred on Friday, July 21st. The shares were sold at an average price of $83.03, for a total value of $878,291.34. Following the completion of the sale, the director now owns 42,151 shares of the company’s stock, valued at approximately $3,499,797.53. The disclosure for this sale can be found here. Insiders sold 71,496 shares of company stock valued at $5,916,223 in the last quarter. Corporate insiders own 12.20% of the company’s stock.
About Danaher Corporation
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Receive News & Ratings for Danaher Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher Corporation and related companies with MarketBeat.com's FREE daily email newsletter.